Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Adaptive Biotechnologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Adaptive Biotechnologies's regulatory disclosures and financial reporting.
Adaptive Biotechnologies officer Francis Lo, the Chief People Officer, reported option exercises and a related stock sale for company shares. On December 22, 2025, Lo exercised stock options to acquire 1,100 shares at $7.80, 1,100 shares at $8.46, and 2,194 shares at $3.99 per share, then sold 4,394 shares of common stock at a weighted-average price of $17.50. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. After the transactions, Lo directly beneficially owned 315,978 shares of common stock and held additional indirect ownership of 2,500 shares through spouse You Jin Lee, along with multiple remaining stock option positions.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported selling 124,998 shares of the company’s common stock on January 5, 2026 at a weighted average price of $15.59 per share. After this sale, he beneficially owned 2,584,243 shares directly.
The transaction was coded as an open market or private sale and was carried out under a Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. The filing notes that the shares were sold in multiple trades at prices ranging from $15.31 to $15.96, and that detailed trade-by-trade information is available upon request.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an option exercise and matching share sale under a pre-set trading plan. On January 2, 2026, Lo exercised a stock option for 3,125 shares of common stock at an exercise price of $3.99 per share and then sold 3,125 shares of common stock at a weighted-average price of $16.08 per share. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025, which is designed to structure trades in advance. After these transactions, Lo beneficially owned 315,978 shares of Adaptive Biotechnologies common stock directly and 2,500 shares indirectly through spouse You Jin Lee, along with 104,856 stock options that remain beneficially owned.
Adaptive Biotechnologies Corp’s Chief People Officer reported stock option exercises and a share sale. On December 15, 2025, the officer exercised options to acquire a total of 97,022 shares of common stock at exercise prices of $7.8, $8.46, and $3.99 per share. On the same date, 113,890 shares were sold in an open-market transaction at a weighted-average price of $15.57, with individual sale prices ranging from $15.37 to $16.03, all under a Rule 10b5-1 trading plan adopted on September 15, 2025. Following these transactions, the reporting person directly beneficially owned 315,978 shares of common stock and indirectly owned 2,500 shares through a spouse, and continued to hold multiple vested stock options.
Adaptive Biotechnologies director Robert Hershberg reported an open-market sale of company stock. On 12/10/2025, he sold 22,968 shares of Adaptive Biotechnologies common stock at a price of $16 per share.
Following this transaction, Hershberg now beneficially owns 46,722 shares of Adaptive Biotechnologies common stock, held directly. The filing identifies him as a director of the company and shows that the report was filed for a single reporting person.
Adaptive Biotechnologies (ADPT) reported insider transactions by its Chief Commercial Officer, Immune Medicine, Sharon Benzeno. On November 20–21, 2025, she executed multiple stock option exercises and related sales of common stock under a Rule 10b5-1 trading plan adopted on August 18, 2025.
She exercised options covering 133,032, 68,961, 834, 20,834, 49,480, 34,375, 119,809 and 83,145 shares at exercise prices between $3.99 and $12.14 per share, converting them into common stock. She then sold 297,925 shares at a weighted average price of $16.54 and 308,477 shares at a weighted average price of $16.91 in multiple transactions within stated price ranges.
Following these transactions, she directly beneficially owns 296,791 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp (ADPT) reported an insider transaction by its Chief Financial Officer on a Form 4. On 11/17/2025, the CFO sold 238 shares of common stock at a price of $14.05 per share. After this transaction, the CFO beneficially owned 269,343 shares of Adaptive Biotechnologies common stock directly.
The company explains that this sale was made solely to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). The transaction was carried out under the issuer’s equity incentive plan, which requires a mandatory "sell to cover" to satisfy tax obligations, so it was not a discretionary trade by the reporting person.
Adaptive Biotechnologies (ADPT) disclosed an insider transaction by its Chief Scientific Officer.
On 11/10/2025, Harlan S. Robins sold 10,000 shares of common stock at a weighted average price of $14.82, with trades ranging from $14.58 to $15.05, pursuant to a Rule 10b5-1 trading plan adopted on August 11, 2025. Following the sale, he beneficially owned 1,269,524 shares held directly.
Adaptive Biotechnologies (ADPT) insider activity: CEO and Chairman Chad M. Robins reported open-market sales of common stock executed under a Rule 10b5-1 trading plan adopted on August 11, 2025. On November 10, he sold 86,161 shares at a weighted average price of $14.73, followed by 1,237 shares at $14.57 on November 11, and 1,867 shares at $15.00 on November 12. After these transactions, he beneficially owned 2,869,975 shares directly. The prices reflect weighted averages across multiple trades within disclosed ranges.
Adaptive Biotechnologies (ADPT) reported stronger Q3 2025 results. Revenue rose to $93.973 million from $46.435 million a year ago, and the company posted net income of $9.545 million (basic and diluted EPS $0.06) versus a prior-year loss. Year-to-date revenue reached $205.295 million with a net loss of $45.878 million.
Growth reflected higher MRD service revenue and a spike in Immune Medicine collaboration revenue, including $33.742 million recognized from the Genentech collaboration. On August 13, 2025, the Genentech Agreement was terminated (effective February 9, 2026); remaining deferred revenue was recognized and the company is no longer eligible for future milestones or royalties.
Cash and cash equivalents were $55.034 million, with $157.735 million in short‑term marketable securities. Deferred revenue decreased to $42.543 million from $82.945 million at year‑end, reflecting revenue recognition. The revenue interest liability, net, was $131.838 million with an effective interest rate of 8.8%. Shares outstanding were 152,665,188 as of October 31, 2025.